PATENT

ATTORNEY DOCKET NO.: 056291-5174 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
GELLERT et al.)
Application No.: 10/505,231) Group Art Unit:
Filed: August 19, 2004) Examiner:
FOR: PHARMACEUTICAL FORMULATION OF IRESSA COMPRISING A WATER-SOLUBLE CELLULOSE DERIVATIVE)))
Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window, Mail Stop Randolph Building 401 Dulany Street Alexandria, VA 22314	Date: January 18, 2005
· Sir:	

REQUEST FOR ENTRY OF PREVIOUSLY FILED **CHANGE OF CORRESPONDENCE ADDRESS**

Please enter in the above-identified application the Change of Correspondence Address previously filed herein by facsimile on September 14, 2004. A copy of the September 14, 2004 Submission of Supplemental Application Data Sheet and Change of Address is attached for reference.

In accordance therewith, the correspondence Address for the above identified application should be changed to Customer Number 09629, with correspondence being addressed to Donald J. Bird at the address below.

It is believed that the previously filed Change of Correspondence Address has not been put into effect inasmuch as the undersigned has been unable to access this application through the above Customer Number in the U.S. Patent and Trademark Office PAIR website.

Respectfully Submitted,

Morgan Lewis & Bockius LLP

Date: January 18, 2005 Morgan Lewis & Bockius LLP Customer No. **09629** 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000

DJB:mk

Donald J. Bird

By:

Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

PAX TRANSMISSION

DATE: September 14, 2004

PTO IDENTIFIER: Application Number 10/505231

Patent Number

Inventor: Gellert et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (703) 872-9306

FROM: ROPES & GRAY LLP

David P. Halstead, Ph.D.

PHONE: (617) 951-7615

Attorney Dkt. #: ASZD-P01-724

PAGES (Including Cover Sheet): 6

CONTENTS: Transmittal (1 page);

Change of Address (1 page);

Application Data Sheet (3 pages); and This facsimile cover sheet (1 page).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7615 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP

One International Place, Boston, Massachusetts 02110-2624 **Telephone:** (617) 951-7000 **Facsimile:** (617) 951-7050

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re. Application of: Gellert et al.

Serial No: 10/505231

Filing Date: August 19, 2004

For: PHARMACEUTICAL FORMULATION OF IRESSA COMPRISING A WATER-SOLUBLE CELLULOSE DERIVATIVE Attorney Docket No. ASZD-P01-724

Art Unit:

Not Yet Assigned

Examiner:

Not Yet Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-9306, on the date shown below.

September 14, 2004

Date of Signature and of Mail Deposit

Mary lane DiPalma

SUBMISSION OF SUPPLEMENTAL APPLICATION DATA SHEET AND CHANGE OF ADDRESS

Applicants submit a supplemental Application Data Sheet and Change of Address to correctly identify the Correspondence and Representative Customer Number as noted on the executed Declaration and Power of Attorney that was filed with the application.

Date: September 14, 2004

Customer No: 28120
Ropes & Gray LLP
One International Place
Boston, MA 02110
Phone: 617-951-7615

Fax: 617-951-7050

Respectfully Submitted,

David P. Halstead, Ph.D.

Reg. No: 44,735





Application Information

Application number:: 10/505231

Filing Date:: 08/19/04

Application Type:: Regular

Subject Matter:: Utility

Suggested Group Art Unit:: N/A

CD-ROM or CD-R?:: None

Sequence submission?:: None

Computer Readable Form (CRF)?:: No

Title:: PHARMACEUTICAL FORMULATION OF

IRESSA COMPRISING A WATER-

SOLUBLE CELLULOSE DERIVATIVE

Attorney Docket Number:: ASZD-P01-724

Request for Early Publication?:: No

Request for Non-Publication?:: No

Small Entity?:: No

Petition included?:: No

Secrecy Order in Parent Appl.?:: No

Applicant Information

Applicant Authority Type:: Inventor

Primary Citizenship Country:: United Kingdom

Status:: Full Capacity

Given Name:: Paul

Middle Name:: Richard

Family Name:: Gellert

City of Residence:: Cheshire

Country of Residence:: United Kingdom

Street of mailing address:: AstraZeneca R&D Alderley

Aldererley Park



Macclesfield

City of mailing address::

Cheshire

Country of mailing address::

United Kingdom

Postal or Zip Code of mailing address::

SK10 4TG

Applicant Authority Type::

Inventor

Primary Citizenship Country::

United Kingdom

Status::

Full Capacity

Given Name::

Michael

Middle Name::

Davis

Family Name::

Parker

City of Residence::

Cheshire

Country of Residence::

United Kingdom

Street of mailing address::

AstraZeneca

Charter Way

Macclesfield

City of mailing address::

Cheshire

Country of mailing address::

United Kingdom

Postal or Zip Code of mailing address::

SK10 2NA

Applicant Authority Type::

Inventor

Primary Citizenship Country::

United Kingdom

Status::

Full Capacity

Given Name::

Marcel

Family Name::

De Matas

City of Residence::

Cheshire

Country of Residence::

United Kingdom

Street of mailing address::

AstraZeneca R&D Alderley

Aldererley Park

Macclesfield

City of mailing address::

Cheshire

Country of mailing address::

United Kingdom

Postal or Zip Code of mailing address:: Sk

SK10 4TG

Correspondence Information

Correspondence Customer Number:

009629

Representative Information

Representative Customer Number::

009629

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
10/505231	National Stage of	PCT/GB03/00803	02/24/03

Foreign Priority Information

Country::	Application number::	FilingDate::	Priority Claimed::
United Kingdom	0204392.5	02/26/02	Yes
United Kingdom	0212462.6	05/30/02	Yes
United Kingdom	0213267.8	06/11/02	Yes

Assignee Information

Assignee name::

AstraZeneca AB

Street of mailing address::

R&D Headquarters

Global Intellectual Property Patents

City of mailing address::

Södertälje

Country of mailing address::

Sweden

Postal or Zip Code of mailing address::

SE-151 85

JAN 1 8 2005 월

COPY

PTO/SB/122 (06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pape Work Reduction Act of 1995, no personal CHANGE OF CORRESPONDENCE ADDRESS Application

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

to respond to a concedent of information direct it explicit			
Application Number	10/505231		
Filing Date	August 19, 2004		
First Named Inventor	Paul Richard Gellert		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket No.	ASZD-P01-724		

Please change the Correspondence Address for the above-identified application to:						
x Customer Number: 009629						
OR						
Firm or Individual Name						
Address	1111 Pennsylvania Avenue, N.W.	1.				
City	Washington	State	D.C.		Zip	20004
Country	US					
Telephone	(202) 739-3000		Fax	(202) 7	39-30	01
data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124). I am the: Applicant/Inventor Assignee of record of the entire interest. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). X Attorney or Agent of record. Registration Number 44,735 Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number						
Typed or Printed Name David P. Halstead, Ph.D.						
Signature SSW SS						
Date September 14, 2004 Telephone (617) 951-7615						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of1 forms are submitted.						

I hereby certify that this correspondence is being	facsimile transm	itted to the	Patent and Trademark Office, facsimile no. (703) 872-
9306, on the date shown below.	5.	9.	P. P. Que Trans Dipoleman

Dated: September 14, 2004

Signature:

(Mary Jane DiPalma)